COLLNasdaqPharmaceutical PreparationsUS GAAP · USD

Collegium Pharmaceutical, Inc

Collegium Pharmaceutical, Inc. is a U.S.-based specialty pharmaceutical company focused on commercializing branded products for pain, attention deficit hyperactivity disorder (ADHD), and opioid-induced constipation. Its portfolio includes Xtampza ER, Belbuca, Jornay PM, the Nucynta Products, and Symproic, all sold primarily in the United States. The company’s business model depends on maintaining access to prescribers, payors, and a concentrated wholesale distribution network while managing the regulatory and reputational complexity of opioid and stimulant therapies. Collegium also relies heavily on third-party manufacturing and limited-source active pharmaceutical ingredient supply, which makes supply continuity a central part of its operating model.

Ask about the company
Revenue781m USD
+23.6 %y/y
Operating profit (EBIT)180m USD
+5.7 %y/y
EBIT margin23.0%
−3.9 ppy/y
Net income62.9m USD
−9.1 %y/y
Free cash flow328m USD
+61.1 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

0200400600800m USD2020: 310 m USD2020: EBIT 56 m USD20202021: 277 m USD2021: EBIT 18 m USD20212022: 464 m USD2022: EBIT 33 m USD20222023: 567 m USD2023: EBIT 167 m USD20232024: 631 m USD2024: EBIT 170 m USD20242025: 781 m USD2025: EBIT 180 m USD2025781180
RevenueOperating profit (EBIT)
Ask Clarifo about Collegium Pharmaceutical, Inc

Business

Share of revenue
Pain portfolio70 %

Branded opioid and pain-management products including Xtampza ER, Belbuca, and the Nucynta Products.

ADHD portfolio20 %

Jornay PM, a branded stimulant therapy marketed for pediatric and adolescent ADHD.

Opioid-induced constipation10 %

Symproic, an oral treatment for opioid-induced constipation in adult patients with chronic non-cancer pain.

Products

Reported · share of revenue
28.4%25.5%19.1%14.8%10.4%FY2025100 %
  • Belbuca28.4 %
  • Xtampza ER25.5 %
  • Jornay Pm19.1 %
  • Nucynta IR14.8 %
  • Nucynta ER10.4 %
  • Symproic and Other1.9 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

Collegium sells primarily through wholesale pharmaceutical distributors, which then supply retail pharmacies, managed care organizations, and government channels. Its pain portfolio is marketed to pain specialists and other prescribers of branded extended-release opioids, while Jornay PM is targeted to clinicians who write pediatric and adolescent extended-release stimulant prescriptions. The company also relies on market-access teams to secure formulary placement and negotiate with payors, because reimbursement strongly influences uptake in branded pharmaceuticals. End customers ultimately include patients treated for chronic pain, ADHD, and opioid-induced constipation, but the immediate buying decision is driven by distributors, payors, and prescribing physicians.

Wholesale pharmaceutical distributors

Buy product inventory in bulk and distribute it to pharmacies and other channels; they are the key commercial gatekeepers for U.S. product access.

Pain specialists and chronic pain prescribers

Prescribe Xtampza ER, Belbuca, and Nucynta Products based on efficacy, dosing convenience, and abuse-deterrence profile.

ADHD prescribers

Prescribe Jornay PM for pediatric and adolescent ADHD patients, valuing differentiated release profile and clinical fit.

Managed care and payor organizations

Influence access through formulary approval, rebates, and contracting, which affect net pricing and volume.

Retail pharmacies and institutional end users

Receive products from wholesalers and dispense them to patients in retail, hospital, clinic, nursing home, and mail-order settings.

Strategy

Collegium’s strategy is centered on defending and expanding its branded pain and ADHD franchises through differentiated product positioning, field sales execution, and payor access. The company emphasizes product attributes such as dosing convenience, safety, and abuse-deterrence for pain therapies, while educating clinicians on the risks associated with opioids and stimulants. It also seeks to improve formulary coverage and contracting through a dedicated market-access team, which is important because reimbursement can materially affect prescription volume. On the supply side, the company is working through manufacturing transitions and third-party production arrangements to support continuity and future growth.

Defend and grow the pain portfolioShort term

Pain products remain the core revenue engine, so maintaining prescriber share and access is essential to offset competition from branded, generic, and non-opioid alternatives.

Expand Jornay PM adoptionMedium term

Jornay PM adds diversification into ADHD and can reduce dependence on the pain franchise if commercial execution improves.

Strengthen market access and payer contractingShort term

Net revenue depends on rebates, chargebacks, and formulary placement, making access management central to volume and pricing realization.

Secure manufacturing and API supply continuityMedium term

Limited-source APIs and outsourced manufacturing create supply risk that can interrupt commercialization if not managed tightly.

Geography

Collegium’s business is overwhelmingly concentrated in the United States, where it commercializes all of its core products and maintains its sales forces and market-access organization. The company’s pain sales force calls on about 10,000 health care professionals, and its ADHD sales force calls on about 21,000 health care professionals, both within the U.S. market. Manufacturing is also U.S.-based but outsourced to third-party partners in Wisconsin, Pennsylvania, Minnesota, Ohio, and previously Puerto Rico for certain packaging activities. This geographic concentration means the company is exposed to U.S. prescription trends, FDA and state-level opioid regulation, and domestic wholesaler consolidation rather than broad international demand diversification.

Risks

Collegium faces concentrated commercial risk because a significant share of shipments goes through only a few wholesale distributors, and any disruption or loss of those accounts could materially affect sales. The company also depends on sole-source or limited-source API suppliers, so manufacturing interruptions, quality issues, or supply-chain disruptions could quickly constrain product availability. Its portfolio is exposed to intense competition from branded, generic, and non-opioid alternatives, while opioid and stimulant products face additional regulatory, pricing, and reputational pressure. Debt service, royalty obligations, and contingent payments add financial risk, and the company’s profitability depends on sustaining commercial performance across a relatively small number of products.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Wholesale distributor concentration1API supply dependence2Opioid regulatory and litigation environment3Competitive pressure in pain and ADHD4Debt and refinancing risk5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Wholesale distributor concentrationImpact: HighLikelihood: Medium

    A significant percentage of shipments go to three wholesale pharmaceutical distributors, so account loss or reduced purchases would directly affect revenue and bargaining power.

    Exposure: U.S. channel concentration

  2. API supply dependenceImpact: HighLikelihood: Medium

    The company relies on a sole supplier or limited number of suppliers for active pharmaceutical ingredients, making it vulnerable to production failures and supply disruptions.

    ExposureXtampza ERNucynta ProductsOther portfolio products
  3. Opioid regulatory and litigation environmentImpact: HighLikelihood: Medium

    State and federal measures can impose taxes, take-back funding, prescribing limits, and compliance burdens on opioid manufacturers.

    Exposure: Pain portfolio

  4. Competitive pressure in pain and ADHDImpact: MediumLikelihood: Medium

    Products compete against branded, generic, and non-opioid alternatives, which can reduce prescriptions and force pricing concessions.

    ExposureXtampza ERBelbucaNucynta ProductsJornay PM
  5. Debt and refinancing riskImpact: MediumLikelihood: Medium

    Substantial indebtedness and convertible notes require ongoing cash generation and may constrain capital allocation.

    Exposure: 2025 Term Loan and 2029 Convertible Notes

Ask Clarifo about Collegium Pharmaceutical, Inc

Accounting

Judgemental items
Net revenue reserves

Revenue is reduced by estimated chargebacks, rebates, sales incentives, distribution fees, and returns, so reserve accuracy directly affects reported sales.

Impact: Can materially shift quarterly revenue and margins

Intangible asset amortization

Acquired product rights and other intangibles are amortized through cost of product revenues, affecting gross profit and operating leverage.

Impact: Large impact on gross margin

Goodwill and intangible impairment

Acquisition-related assets must be tested for impairment if product performance or market conditions weaken.

Impact: Potential non-cash write-downs

Contingent consideration and royalty liabilities

Milestone-based payments and royalty arrangements depend on future product performance and fair value estimates.

Impact: Can create earnings volatility

Similar listed companies

Publicly listed companies with a comparable business focus.

Contineum Therapeutics, Inc.

CTNM · Pharmaceutical Preparations

Lexaria Bioscience Corp.

LEXX · Pharmaceutical Preparations

Assertio Holdings, Inc.

Pharmaceutical Preparations

Semnur Pharmaceuticals, Inc.

SMNR · Pharmaceutical Preparations

Corcept Therapeutics Incorporated

CORT · Pharmaceutical Preparations

Lexicon Pharmaceuticals, Inc

LXRX · Pharmaceutical Preparations

Last updated: 24/09/2026